13 risultati
FIELD OF THE INVENTION
This invention relates to hyperthermic treatment of hepatitis C.
BACKGROUND OF THE INVENTION
Injected drug users are the largest group of people with hepatitis C infection. People who received a blood transfusion or kidney transplant before a diagnostic test became available
FIELD OF THE INVENTION
This invention relates to hyperthermic treatment of hepatitis C.
BACKGROUND OF THE INVENTION
Injected drug users are the largest group of people with hepatitis C infection. People who received a blood transfusion or kidney transplant before a diagnostic test became available
FIELD OF THE INVENTION
This invention relates to hyperthermic treatment of hepatitis C.
BACKGROUND OF THE INVENTION
Injected drug users are the largest group of people with hepatitis C infection. People who received a blood transfusion or kidney transplant before a diagnostic test became available
BACKGROUND OF THE INVENTION
The invention relates generally to the use of sesquiterpene lactones in the treatment of infections caused by Flaviviridae and, more specifically, to the use of sesquiterpene lactone endoperoxides to treat hepatitis C infections, yellow fever, dengue fever, bovine viral
FIELD OF THE INVENTION
This invention relates to the anti-viral drugs such as Helioxanthin and its analogs compounds. These compounds may be used alone or in combination with other drugs for the treatment of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus,
SEQUENCE LISTING
The sequence listing contained in the electronic file "2016-05-01 1464.8005_ST25.txt" created on May 2, 2016, comprising 60 KB is incorporated herein by reference".
FIELD OF THE INVENTION
This disclosure relates to rapid methods for real-time multiplex detection and identification
This application is the U.S. national phase of International Application No. PCT/CN2011/083357 filed 2 Dec. 2011 which designated the U.S. and claims priority to CN 201010581618.3 filed 9 Dec. 2010, the entire contents of each of which are hereby incorporated by reference.
TECHNICAL FIELD
The
FIELD OF THE INVENTION
The present invention includes (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleosides having the natural .beta.-D configuration and methods for the treatment of Flaviviridae infections, especially hepatitis C virus (HCV).
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection
FIELD OF THE INVENTION
The present invention includes (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleosides having the natural .beta.-D configuration and methods for the treatment of Flaviviridae infections, especially hepatitis C virus (HCV).
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection
FIELD OF THE INVENTION
The present invention includes (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleosides having the natural .beta.-D configuration and methods for the treatment of Flaviviridae infections, especially hepatitis C virus (HCV).
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection
FIELD OF THE INVENTION
This invention is directed to novel compounds which are useful in the treatment of viral infections. The invention is also directed to pharmaceutical compositions containing the compounds, processes for their preparation and uses of the compounds in various medicinal
FIELD OF THE INVENTION
This invention is directed to novel compounds which are useful in the treatment of viral infections. The invention is also directed to pharmaceutical compositions containing the compounds, processes for their preparation and uses of the compounds in various medicinal
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable.
BACKGROUND
The unstable nature of the RNA molecule enables RNA viruses to evolve far more rapidly than DNA viruses, frequently changing their surface structures. RNA viruses in general have very high mutation rates as